tallózása szerző szerint "Kudaba I,"

1-1 / 1

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Markoczy Z,; Sárosi, Veronika; Kudaba I,; Gálffy, Gabriella; Turay UY,; Demirkazik A; Purkalne G; Somfay, Attila; Papai-Szekely Z; Rásó, Erzsébet; Ostoros G (2018)

BACKGROUND: Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated ...

1-1 / 1

Keresés